Osocimab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Osocimab
- bay 1213790
- BAY 1213790
- BAY-1213790
- bay1213790
- Bay1213790
- BAY1213790
- BAY1213790 (Osocimab)
- bay1213790 osocimab
- immunoglobulin g1 anti human blood coagulation factor xia human monoclonal bay 1213790 gamma 1 chain disulfide with human monoclonal bay 1213790 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN BLOOD-COAGULATION FACTOR XIA) (HUMAN MONOCLONAL BAY 1213790 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL BAY 1213790 .KAPPA.-CHAIN, DIMER
- osocimab
- Osocimab
- osocimab [INN]
- Osocimab [WHO-DD]
- osocimab inn
- osocimab who dd
- CAS registry numbers
- 2056878-75-0
- ChEMBL ID
- CHEMBL4297905
- FDA ingredient codes (UNII)
- EK5V9UL3WL
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- osocimab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- coagulation factor XI
- Gene symbol
- F11
- Protein identifier
- P03951
- Median affinity
- 8.62
- Affinity units
- pKd
- Mechanism
- Coagulation factor XI negative allosteric modulator
- Action type
- NEGATIVE_ALLOSTERIC_MODULATOR
- Target
- Coagulation factor XI
- Protein identifier
- P03951
Open Targets mechanisms
- Mechanism
- Coagulation factor XI negative allosteric modulator
- Action type
- NEGATIVE ALLOSTERIC MODULATOR
- Target
- Coagulation factor XI
Open Targets indications
- Condition identifier
- MONDO_0000831
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
- End-stage Renal Disease (ESRD) Pilot Study
- FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In development for (1)
- Thrombotic disease Phase 2
Targets (1)
- F11 Coagulation factor XI negative allosteric modulator